MicroRNAs as therapeutic targets for the treatment of diabetes mellitus and its complications.

Détails

Ressource 1Télécharger: 29257914.pdf (552.33 [Ko])
Etat: Public
Version: Author's accepted manuscript
ID Serval
serval:BIB_7B630506C07A
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
MicroRNAs as therapeutic targets for the treatment of diabetes mellitus and its complications.
Périodique
Expert opinion on therapeutic targets
Auteur⸱e⸱s
Regazzi R.
ISSN
1744-7631 (Electronic)
ISSN-L
1472-8222
Statut éditorial
Publié
Date de publication
02/2018
Peer-reviewed
Oui
Volume
22
Numéro
2
Pages
153-160
Langue
anglais
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Résumé
Diabetes mellitus is a very common metabolic disorder affecting more than 400 million people worldwide. Currently available treatments permit to manage the disease but, in the long term, many patients develop severe micro- and macrovascular complications that decrease life quality and expectancy. Better therapeutic tools to prevent and treat diabetes are therefore urgently needed. Areas covered: MicroRNAs are key regulators of gene expression and central players in a variety of physiological and pathological processes. This review summarizes the role of microRNAs in insulin-secreting cells and in insulin target tissues as well as their involvement in the development of diabetes and its long term complications. Expert opinion: Because of their physicochemical properties and their capacity to regulate a wide range of physiopathological events, microRNAs are attractive therapeutic targets. There is accumulating evidence that approaches permitting to correct the level of specific microRNAs can successfully prevent or treat diabetes and its complications. Pharmacological tools that efficiently modulate the level of microRNAs are already available. However, before these tools can be allowed to integrate the arsenal for the treatment of diabetic patients, new innovative strategies will be needed to achieve selective delivery of these pharmacological principles to the appropriate target cells.
Mots-clé
Animals, Diabetes Complications/genetics, Diabetes Complications/physiopathology, Diabetes Complications/therapy, Diabetes Mellitus/genetics, Diabetes Mellitus/physiopathology, Diabetes Mellitus/therapy, Humans, Hypoglycemic Agents/pharmacology, Insulin/metabolism, Insulin-Secreting Cells/metabolism, MicroRNAs/genetics, Molecular Targeted Therapy, Aptamer, diabetes mellitus, diabetic complications, exosome, microRNA
Pubmed
Web of science
Open Access
Oui
Création de la notice
10/01/2018 10:11
Dernière modification de la notice
21/11/2022 9:19
Données d'usage